Stockwinners Market Radar for July 23, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

BABA...

Hot Stocks

20:13 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Alibaba (BABA) said on Sunday it had decided not to participate in affiliate Ant Group's proposed repurchase of shares, but would maintain its shareholding in the company, according to Reuters. Ant Group announced a surprise share buyback of up to 7.6% of its equity interest earlier this month, a day after it was fined $984M by Beijing for violating laws and regulations. 2. An X is going to replace Twitter's blue bird. Elon Musk said in a tweet that, "X.com now points to URL Interim X logo goes live later today." Musk's X Corp owns Twitter. 3. Corporations are shifting budget priorities to experimental artificial-intelligence projects, Tae Kim writes in this week's edition of Barron's. That may be good news for Microsoft (MSFT), but it could just as well turn out to be bad news for tech hardware vendors, the author adds. Companies are prioritizing new AI applications above everything else, and Microsoft may be the big winner from the shift to AI in underlying enterprise spending. But while Microsoft basks in the excitement over AI, other vendors are facing more challenges. TSMC (TSM) reported an overall softening of semiconductor demand, adding that the macroeconomic environment, expectations for China's recovery and end-market demand both looked weaker than they had expected only three months ago, the author notes. 4. Warner Bros.' (WBD) "Barbie" won this weekend at the North American box office with a historic $155M debut. Overseas, the movie opened to $182M from 70 markets for a global cume of $337M. "Barbie" also broke the record in North America for a debut of a film directed by a woman, as Greta Gerwig's pic about the world's famous fashion doll dethroned Patty Jenkins' "Wonder Woman" and Anna Boden & Ryan Fleck's "Captain Marvel." 5. Arthur J. Gallagher (AJG), Rockwell Automation (ROK), Emerson Electric (EMR), Eaton (ETN), Trane Technologies (TT), Amphenol (APH), Keysight Technologies (KEYS), Constellation Brands (STZ), and W.W. Grainger (GWW). saw positive mentions in this week's edition of Barron's.
TSLA TWTR

Hot Stocks

17:09 EDT Elon Musk says Twitter blue bird logo to be replaced by X - An X is going to replace Twitter's blue bird. Elon Musk said in a tweet that, "X.com now points to https://twitter.com/. Interim X logo goes live later today." Musk's X Corp owns Twitter. Reference Link
VATE

Hot Stocks

16:41 EDT INNOVATE Corp. announces passing of CEO Wayne Barr - INNOVATE Corp. announced that Wayne Barr, President, Chief Executive Officer and Director, passed away unexpectedly on July 22, 2023. The Board has appointed Chief Operating Officer Suzi Herbst as Interim Chief Executive Officer.
CVX

Hot Stocks

16:38 EDT Chevron appoints Eimear Bonner as new CFO - Chevron announced several senior leadership changes as well as a waiver of the mandatory retirement age for the chairman and chief executive officer, Mike Wirth. Pierre Breber, vice president and chief financial officer, will retire from Chevron in 2024 after 35 years of distinguished service to the company. Eimear Bonner, currently vice president and chief technology officer and president of the Chevron Technical Center, will succeed Breber as chief financial officer, effective March 1, 2024, the company said. Bonner will report to Wirth in her new role. The company announced several other senior leadership appointments related to this transition. Balaji Krishnamurthy, currently vice president of Strategy & Sustainability, will become vice president of the Chevron Technical Center. Molly Laegeler, currently vice president of Chevron's San Joaquin Valley Business Unit, will become vice president of Strategy & Sustainability. And Frank Mount, currently vice president of M&A and Origination, will become vice president of Business Development. Chevron's independent directors waived the company's mandatory retirement age of 65 for its chairman and chief executive officer, Mike Wirth, who will turn 63 later this year.
EXEL TEVA

Hot Stocks

16:28 EDT Exelixis announces settlement of CABOMETYX patent litigation with Teva - Exelixis (EXEL) announced that it has entered into a Settlement and License Agreement with Teva Pharmaceuticals Development and Teva Pharmaceuticals, collectively Teva (TEVA). This settlement resolves patent litigation brought by Exelixis in response to Teva's Abbreviated New Drug Application seeking approval to market a generic version of CABOMETYX tablets prior to the expiration of the applicable patents. Pursuant to the terms of the Agreement, Exelixis will grant Teva a license to market its generic version of CABOMETYX in the United States beginning on January 1, 2031, if approved by the U.S. Food and Drug Administration and subject to conditions and exceptions common to agreements of this type. Additionally, in accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Exelixis and Teva regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware. The Agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
MEIP

Hot Stocks

16:24 EDT MEI fails to obtain votes to approve merger with Infinity Pharmaceuticals - MEI Pharma announced that, based on a count of the votes cast at the company's Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder votes to approve the merger agreement with Infinity Pharmaceuticals. The certified results show that 59.70% of outstanding shares were voted, of which 47.86% voted in favor of the proposed transaction, and 51.44% against. Accordingly, MEI has sent Infinity a notice terminating the merger agreement. "While we believe the benefits of the Infinity transaction were compelling for MEI stockholders, we appreciate and value the perspectives of our stockholders," said David M. Urso, President and Chief Executive Officer of MEI Pharma. "Our Board and management team remain highly-focused on the potential for capturing the stockholder value inherent in the Company's current development pipeline, which includes Voruciclib and ME-344. With clinical data expected from both of our clinical-stage pipeline programs around year-end and capital to support our near-term development plans, we are focused on the potential opportunities for creating stockholder value."